Table 3.
Outcome measures for the total cohort as well as patients able (strictly personal) and unable to consent (legal representative)
| Total cohort | Strictly personal | Legal representative | P-value | OR (95% CI) | |
|---|---|---|---|---|---|
| Discharge mRS, median (IQR) | 5 (4–5) | 4 (4–5) | 5 (4–5) | < 0.001 | MWU |
| Discharge BI, median (IQR) | 10 (0–35) | 25 (10–40) | 5 (0–20) | < 0.001 | MWU |
| Discharge location, n (%) | Somers‘Δ | 0.094 | |||
| Home | 16 (7.8) | 8 (7.3) | 8 (8.5) | ||
| Rehabilitation hospital | 164 (80.4) | 92 (84.4) | 71 (75.5) | ||
| Other acute care hospital | 17 (8.3) | 8 (7.3) | 9 (9.6) | ||
| Nursing home | 7 (3.4) | 1 (0.9) | 6 (6.4) | ||
| Death in hospital, n (%) | 11 (4.8) | 1 (0.8) | 10 (9.3) | 0.004 | 12.1 (1.5–96.5) |
| mRS at 3 months, median (IQR) | 4 (3–6) | 4 (3–5) | 5 (4–6) | < 0.001 | MWU |
| Any SAE, n (%) | 68 (29.7) | 33 (27.5) | 35 (32.4) | 0.469 | 1.3 (0.7–2.2) |
| During hospitalisation, n (%) | |||||
| Fever | 152 (67.3) | 69 (59.0) | 83 (76.9) | 0.005 | 2.3 (1.3–4.1) |
| Delirium | 19 (8.5) | 8 (6.8) | 11 (10.4) | 0.472 | 1.6 (0.6–4.1) |
| Leukocytosis | 71 (33.6) | 36 (32.1) | 34 (34.7) | 0.770 | 1.1 (0.6–2.0) |
| Mechanical ventilation | 24 (10.8) | 11 (9.4) | 13 (12.4) | 0.521 | 1.4 (0.6–3.2) |
| Infection, n (%) | 99 (43.6) | 44 (37.3) | 54 (50.0) | 0.061 | 1.7 (1.0–2.9) |
| Pneumonia | 65 (28.5) | 32 (26.9) | 33 (30.6) | 0.560 | 1.2 (0.7–2.1) |
| Sepsis | 3 (1.3) | 2 (1.7) | 1 (0.9) | 1.0 | 0.5 (0.1–6.1) |
| Urinary tract infection | 25 (11.0) | 12 (10.1) | 13 (12.0) | 0.676 | 1.2 (0.5–2.8) |
| Other infection | 55 (24.1) | 26 (21.8) | 28 (25.9) | 0.533 | 1.3 (0.7–2.3) |
All p-values given are calculated using Fisher’s exact test except where explicitly stated a Mann-Whitney-U-test (MWU) or Somers’ Δ correlation; Abbreviations: mRS modified Rankin Scale, BI Barthel Index, SAE serious adverse event, PCT procalcitonin